India’s health ministry bans pioglitazone, metamizole, and flupentixol-melitracen

@article{Bhaumik2013IndiasHM,
  title={India’s health ministry bans pioglitazone, metamizole, and flupentixol-melitracen},
  author={Soumyadeep Bhaumik},
  journal={BMJ : British Medical Journal},
  year={2013},
  volume={347}
}
  • S. Bhaumik
  • Published 2013
  • Medicine
  • BMJ : British Medical Journal
India’s ministry of health and family welfare has banned the popular diabetes drug pioglitazone, the painkiller metamizole, and the psychiatric combination flupentixol with melitracen with immediate effect, because it said that their use was “likely to involve risk to human beings.” The move is a response to a report from a parliamentary standing committee in April that criticised the ministry for failing to withdraw several drugs … 
Flip flop policy over pioglitazone licence causes media storm in India
India’s ministry of health and family welfare has revoked the ban that it placed on the antidiabetes drug pioglitazone just six weeks ago because of the drug’s association with bladder cancer.1 TheExpand
Metamizole (Dipyrone) and the Liver: A Review of the Literature
  • M. Lutz
  • Medicine
  • Journal of clinical pharmacology
  • 2019
TLDR
The literature is extensively reviewed for the first time regarding hepatic effects associated with the use of metamizole, a frequently used drug worldwide either legally or illegally. Expand
Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice
TLDR
Dipyrone can be recommended for the treatment of cancer pain as an alternative to other non-opioids either alone or in combination with opioids, and can be preferred over non-steroidal anti-inflammatory drugs due to the presumably favorable side effect profile in long-term use. Expand
Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations
TLDR
The focus is on human leukocyte antigen (HLA) alleles and haplotypes as predictive markers of HSRs (“immunopharmacogenetics”), but other genes and alleles are described as well. Expand
Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012
PurposeIn 1986, the risk of agranulocytosis prompted German authorities to restrict the indications for metamizole use. After an initial decline, prescriptions increased from <20 million definedExpand
Metamizole-Associated Adverse Events: A Systematic Review and Meta-Analysis
TLDR
For short-term use in the hospital setting, metamizole seems to be a safe choice when compared to other widely used analgesics, but high-quality, adequately sized trials assessing the intermediate- and long-term safety of metamzole are needed. Expand
Insulin Resistance Intervention After Stroke Trial of Pioglitazone: Is This Perhaps the End of the Beginning?
TLDR
The completion of the Insulin Resistance Intervention After Stroke (IRIS) trial culminated a long process to test, for the first time, whether treatment with an approved antidiabetic drug at the prediabetic stage of insulin resistance (IR) improves outcomes in patients with cerebrovascular disease. Expand
Trends in Antidepressant Use and Expenditure in Six Major Cities in China From 2013 to 2018
TLDR
The wide use of expensive antidepressants and those with weak clinical evidence raises concerns regarding the rational use of antidepressants, and this study provides a basis for future stewardship by the government and medical institutions. Expand
How Effective Are the 2013 DPCO Regulations
In this chapter, we examine whether the 2013 DPCO has been successful in making essential medicines more affordable. Before we do so, it is useful to recall historical assessments of previousExpand
Role of peroxisome proliferator‐activated receptors in stroke prevention and therapy—The best is yet to come?
TLDR
The aim of this review was to summarize two decades of PPAR research in stroke with emphasis on in vivo animal studies and focus on each PPAR receptor separately and detail their implication in stroke. Expand
...
1
2
...

References

SHOWING 1-2 OF 2 REFERENCES
Committee condemns Indian government for failing to withdraw 33 drugs that lack evidence
A parliamentary committee on health has severely criticised India’s government for its “evasive” response to recommendations it made in May last year on tightening the regulation of drugs. ItExpand
Meta-analysis confirms raised risk of bladder cancer from pioglitazone
A new meta-analysis1 seems to confirm findings from a nested, case-control study published in the BMJ in May2 that thiazolidinediones are associated with an increased risk of bladder cancer in peopleExpand